Foscarnet for Cytomegalovirus Retinitis
1985; American College of Physicians; Volume: 103; Issue: 6_Part_1 Linguagem: Inglês
10.7326/0003-4819-103-6-962_2
ISSN1539-3704
Autores Tópico(s)Neutrophil, Myeloperoxidase and Oxidative Mechanisms
ResumoLetters and Corrections1 December 1985Foscarnet for Cytomegalovirus RetinitisD. R. J. SINGER, M.R.C.P., T. J. FALLON, M.B., Ch.B., W. E. SCHULENBURG, F.R.C.S., G. WILLIAMS, F.R.C.S., J. COHEN, M.SC., M.R.C.P.D. R. J. SINGER, M.R.C.P.Search for more papers by this author, T. J. FALLON, M.B., Ch.B.Search for more papers by this author, W. E. SCHULENBURG, F.R.C.S.Search for more papers by this author, G. WILLIAMS, F.R.C.S.Search for more papers by this author, J. COHEN, M.SC., M.R.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-103-6-962_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: We read with interest the three reports (1-3) of treatment with dihydroxy-propoxymethylguanine (DHPG) in 15 immunocompromised patients with cytomegalovirus infection. It was notable that in 5 patients with retinitis, relapse occurred as early as 4 weeks after the end of DHPG infusion and that daily maintenance treatment was required to sustain remission. Foscarnet (4) is a virostatic agent of importance in the treatment of cytomegalovirus infections after renal and bone marrow transplantation (5). We have recently used foscarnet to treat a patient with the acquired immunodeficiency syndrome and cytomegalovirus retinitis.A white heterosexual man aged 54 years...References1. SHEPP D, DANDLIKER P, and DE MIRANDA P. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med. 1985;103:368-73. LinkGoogle Scholar2. FELSENSTEIN D, D'AMICO D, and HIRSCH M. Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann Intern Med. 1985;103:377-80. LinkGoogle Scholar3. BACH M, BAGWELL S, KNAPP N, DAVIS K, and HEDSTROM P. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine for cytomegalovirus infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1985;103:381-2. LinkGoogle Scholar4. Foscarnet [Editorial]. Lancet. 1985;2:648-9. MedlineGoogle Scholar5. RINGDÉN O, WILCZEK H, LÖNNQVIST B, GAHRTON G, WAHREN B, and LERNESTEDT J. Foscarnet for cytomegalovirus infections. Lancet. 1985;1:1503-4. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: D. R. J. SINGER, M.R.C.P.; T. J. FALLON, M.B., Ch.B.; W. E. SCHULENBURG, F.R.C.S.; G. WILLIAMS, F.R.C.S.; J. COHEN, M.SC., M.R.C.P.Affiliations: Royal Postgraduate Medical School London W12 OHS England PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAIDS and Its Ophthalmic ManifestationsInhibitory effect of hexamethylene bisacetamide on replication of human cytomegalovirusEffect of desferrioxamine (DFO) and calcium trinatrium diethylenetriaminepentaacetic acid (DTPA) on rat cytomegalovirus replication in vitro and in vivoInhibition of Human Cytomegalovirus Proteinase by Salcomine DerivativesIn vitro inhibition of human cytomegalovirus replication by calcium trinatrium diethylenetriaminepentaacetic acidHuman monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): Enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replicationSystemic viral infections and their retinal and choroidal manifestationsPharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patientsSystemic antiviral drugs used in ophthalmologyFoscarnet in the Treatment of Cytomegalovirus Retinitis in Acquired Immune Deficiency SyndromeCombinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitroInhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnetAntiviral effects of phosphonoformate (pfa, foscarnet sodium)The Diagnosis of Cytomegalovirus RetinitisJeffrey N. Bloom, MD, Alan G. Palestine, MDManagement of Viral RetinitisViral infections in the acquired immunodeficiency syndromeTherapy and Prevention of Cytomegalovirus InfectionsClinical Use of Foscarnet (Phosphonoformate)Toxicity of intravitreal injection of foscarnet in the rabbit eyeTreatment of Cytomegalovirus InfectionTreatment of CMV retinitis in an AIDS patient.Acquired Immunodeficiency Syndrome of ChildhoodUse of Intravitreal Ganciclovir (Dihydroxy Propoxymethyl Guanine) for Cytomegalovirus Retinitis in a Patient With AIDSTherapeutic use of newer antiviral agents 1 December 1985Volume 103, Issue 6_Part_1Page: 962-962KeywordsAIDSBone marrow transplantationCytomegalovirus infectionHeterosexualsRetinitis ePublished: 1 December 2008 Issue Published: 1 December 1985 PDF downloadLoading ...
Referência(s)